记者 俞陶然 开幕活动上，诺贝尔生理学或医学奖得主、约翰斯·霍普金斯大学医学院教授格雷格·塞门扎，美国 科学院院士、中国科学院外籍院士、百济神州联合创始人王晓东，中国科学院院士、北京大学李兆基讲 席教授谢晓亮等顶尖科学家将发表演讲。来自产业界的国内外代表也将分享真知灼见。 一系列仪式活动将在本届产业周上举行，包括：上海生物医药技术性贸易措施研究评议基地揭牌、 2025上海国际计算生物学创新大赛获奖名单发布、上海国投生物医药产业生态合作基金签约、上海高端 医疗器械集聚区启动。 记者昨天从市科委获悉，10月13日至17日，2025上海国际生物医药产业周将在张江科学会堂举行。 本届产业周以"链动全球 赋能产业"为主题，采用"1+1+15+N"架构，包括一场开幕活动、一场同期举办 的成果展览、15场系列专题论坛以及全年多场产业周系列主题活动。 本届产业周将汇聚国际科技大奖得主、国内外院士、数百位学术界和临床医疗专家，以及千余位知 名药企、投资机构、生态服务伙伴代表。 作为上海新一轮生物医药产业布局的两个重要集聚区，浦东新区和闵行区将分别介绍两区的相关政 策，并通过政企沟通闭门会等系列专题论坛，呈现区域生物医药特色布局 ...

中新网上海10月9日电(记者郑莹莹)2025上海国际生物医药产业周将于10月13日至10月17日举办。上海 市科委生物医药处处长、二级巡视员曹宏明9日在相关会议上介绍，上海生物医药产业规模持续增长， 从2021年的7617.14亿元增长至2024年的9847.02亿元，年均复合增长率为8.94%；2025年上半年达 5005.66亿元，预计今年将突破1万亿元。 上海是中国生物医药产业的创新高地。1993年，上海率先将现代生物与医药产业列为重点发展的高新技 术产业。目前，生物医药是上海重点发展的三大先导产业之一。 截至2024年年末，上海生物医药规上企业达2183家，涵盖制造、服务、批发等多个行业。国际排名前20 位的药企和排名前20位的医疗器械企业中，各有19家在上海设立总部、生产中心或研发中心。 曹宏明表示，2021年以来，上海已有9款药品在美国、日本、印度尼西亚等国家和地区获批上市。 同时，上海在相关领域的外商投资准入有序放开，已有33家外商投资企业参与上海在人体干细胞、基因 诊断与治疗技术的开发和应用试点，有30家外资医疗机构在上海市设立并投入运营。 2024年，上海成立总规模为225亿元的上海生物医药 ...

值得一提的是，百奥赛图的发展也离不开大兴区的产业土壤。作为北京生物医药产业的集聚高地，大兴 区不断加快"国际生命健康产业创新区"建设步伐，打造从研发、孵化到产业化的全链条生态。大兴政府 为百奥赛图提供了良好的政策环境与产业配套，从研发平台到人才队伍建设，都给予了积极支持。百奥 赛图也因此能够依托大兴，放眼全球，在创新药领域持续深耕。 "我们不只是一家小鼠公司。"正如百奥赛图董事长沈月雷所言，公司不仅提供靶点人源化小鼠，更通过 候选抗体分子授权，形成指数型增长的业务模式。随着抗体分子库的不断扩充，百奥赛图正在筑起更高 的行业壁垒，向着"全球新药发源地"这一目标稳步迈进。 当前，国家层面对生物医药产业的支持力度空前，鼓励更多企业走出国门、面向国际市场。百奥赛图作 为从大兴走向世界的代表企业，正是这一政策导向下的典型缩影。它不仅以创新技术填补了我国新药研 发的底层短板，也在全球创新药产业链中展现出"中国方案"的独特价值。 在国家大力推动生物医药产业高质量发展的今天，生物医药被正式纳入战略性新兴产业和未来产业重点 布局方向。政策层面不断强调加快新药研发、完善创新生态、支持关键技术突破，这为行业带来前所未 有的发展机遇 ...

值得注意的是，国家药监局药审中心、器审中心等六大中心皆已落地北京经开区，国家药监局京津冀分 中心同步落地，设立国家药监局器械审查的创新服务站，赋能北京经开区生物医药产业发展。 新京报讯（记者张秀兰）中国医药新闻信息协会近日组织主流媒体记者走访北京经济技术开发区（以下 简称北京经开区）。目前，北京经开区已入驻5300多家生物医药市场主体，25家生物医药上市公司，拥 有生物医药产业从业人员5万多名。 唯迈医疗公司是此次走访的第一站，公司旗下的介入手术机器人为国家首个三类医疗器械创新通道获批 的自研国产高端装备。入驻北京经开区多年来，唯迈医疗已成长为国家级专精特新"小巨人"、国家级高 新技术、北京市首批两业融合试点企业，产品远销全球40多个国家和地区。 作为首都高精尖产业的主阵地、医药健康产业的主要承载区，北京经开区已走过30余年的发展历程，目 前已入驻5300多家生物医药市场主体，25家生物医药上市公司，生物医药产业从业人员5万多名，已建 成300万平方米生物医药产业发展空间，集全市资源打造BioPark国际医药创新公园。 为支持生物医药产业发展，北京经开区出台了积极产业扶助政策，对一类创新药临床Ⅱ/Ⅲ期支持10 ...

昨天（9月19日），苏州市委书记刘小涛会见了赛默飞世尔科技中国区总裁方明杰一行。 倪黎祥 摄 会见中，刘小涛代表市委、市政府对赛默飞给予苏州发展的支持表示感谢。他说，苏州高度重视生物医药产 业发展，汇聚了一批优质项目、创新人才、产业基金，打造了一系列创新药和医疗器械产品，推动产业呈现蓬勃 发展态势。当前，我们正积极抢抓生物医药全产业链开放创新发展机遇，打造生物医药产业发展高地。赛默飞是 行业领先企业，与苏州合作基础深厚、合作空间广阔。欢迎赛默飞继续扎根苏州、深耕苏州，导入更多先进技 术、创新产品，并加强与苏州本土企业合作，为苏州生物医药产业发展注入新活力、增添新动能。我们将积极营 造市场化、法治化、国际化一流营商环境，助力企业实现更好发展。 方明杰对苏州给予赛默飞的支持帮助表示感谢。他说，苏州是赛默飞在华投资额最大的城市之一。受益于当 地良好的营商环境，赛默飞在苏项目进展顺利，取得了丰厚回报。面向未来，我们积极看好苏州生物医药产业发 展前景，将持续扩大在苏投资布局，进一步提升本土研发和生产能力，并加强与苏州产业链供应链对接合作，助 力苏州生物医药产业创新发展。 市委常委、副市长唐晓东，苏州高新区主要负责同志参 ...

Core Viewpoint - The article discusses the recent developments in the Shenzhen real estate market, highlighting the impact of government policies and market dynamics on property prices and sales volume [1] Group 1: Market Trends - Shenzhen's property prices have shown a significant increase, with a year-on-year rise of 12% in the last quarter [1] - The sales volume in the residential sector has surged, reaching 50,000 units sold in the past month, marking a 30% increase compared to the previous month [1] Group 2: Government Policies - Recent government measures aimed at stimulating the housing market include lowering mortgage rates and providing subsidies for first-time homebuyers [1] - The local government has also implemented policies to increase land supply, which is expected to stabilize prices in the long term [1] Group 3: Investor Sentiment - Investor confidence in the Shenzhen real estate market is on the rise, driven by favorable economic indicators and government support [1] - The article notes that institutional investors are increasingly looking to enter the market, anticipating further price appreciation [1]

Core Insights - The Guangdong-Hong Kong-Macao Greater Bay Area Entrepreneurship Competition held its semifinals in Zhuhai, showcasing 90 projects in two tracks: healthcare and biomanufacturing, and modern services and cultural creativity, with 30 projects advancing to the finals [2][4] Group 1: Project Performance - A total of 142 projects from Hong Kong and Macao advanced to the semifinals, accounting for 31.6% of the total, highlighting the vitality of the region and the integration within the Greater Bay Area [4] - Notable projects include a mesenchymal stem cell culture system developed by a team from the University of Macau, which aims to tap into the clinical application market in the Greater Bay Area [5][7] - Another project focused on human-derived islet organ therapy for diabetes, incubated by the University of Hong Kong, has established connections with investment institutions and shows clear intentions to land in Guangdong [7] Group 2: Resource Integration and Support - The competition serves as a platform for startups to connect with capital and market resources, with multiple resource matching activities taking place during the semifinals [9] - The Guangdong Zhuhai Public Entrepreneurship Incubation Base has facilitated connections for 11 entrepreneurial projects from across the country seeking opportunities in the Greater Bay Area [9] - The base offers initiatives like the "Pearl River Delta University Student Entrepreneurship Support Program" to help young entrepreneurs from Hong Kong and Macao integrate into the Greater Bay Area [9] Group 3: Government and Policy Support - The government provides substantial support for the biotechnology sector, with a complete industrial chain from research and development to distribution, which is attractive for young entrepreneurs [10] - The establishment of the Hengqin Youth Entrepreneurship and Employment Association aims to facilitate the implementation of the "Macao Youth Entrepreneurship Support Policy," providing comprehensive services for project landing [10]

Core Viewpoint - The State-owned Assets Supervision and Administration Commission (SASAC) emphasizes the acceleration of the development of the biopharmaceutical industry among central enterprises, focusing on innovation-driven, long-cycle, and differentiated development to enhance the industry's quality and impact [1] Group 1: Industry Development - SASAC, in collaboration with the Chinese Academy of Sciences, held a senior training course for central enterprises in the biopharmaceutical sector from August 27 to 30 [1] - The initiative aims to align with the "Healthy China" strategy and promote high-quality development in the biopharmaceutical industry [1] - There is a focus on deep learning, brainstorming, and precise understanding of industry trends and development paths for central enterprises [1] Group 2: Corporate Actions - In March, SASAC encouraged state-owned enterprises to utilize mergers and acquisitions, equity investments, and industrial funds to strengthen their influence in underdeveloped sectors like biopharmaceuticals [1] - Recently, China National Pharmaceutical Group (Sinopharm) announced acquisitions of leading companies in the blood products sector, Palin Biotech, and the pharmaceutical glass industry leader, Shandong Pharmaceutical Glass, showcasing a trend in industry consolidation [1]

Core Viewpoint - The State-owned Assets Supervision and Administration Commission (SASAC) is focusing on accelerating the development of the biopharmaceutical industry among central enterprises, emphasizing innovation-driven, long-cycle, and differentiated development to enhance the industry's quality and impact [1]. Group 1: Industry Development - SASAC, in collaboration with the Chinese Academy of Sciences, held a high-level training course for central enterprises in the biopharmaceutical sector from August 27 to 30 [1]. - The initiative aims to align with the "Healthy China" strategy and promote high-quality development in the biopharmaceutical industry [1]. - SASAC encourages state-owned enterprises to utilize mergers and acquisitions, equity investments, and industrial funds to strengthen their influence in the biopharmaceutical sector, particularly in areas with weak industrial foundations [1]. Group 2: Recent Mergers and Acquisitions - Recently, China National Pharmaceutical Group (Sinopharm) announced the acquisition of leading companies in the blood products sector, including Palin Biotech, and in the pharmaceutical glass sector, Shandong Pharmaceutical Glass, marking significant examples of mergers in the pharmaceutical industry [1].

Group 1: International Relations and Trade - China will implement a visa-free policy for Russian citizens holding ordinary passports from September 15, 2025, to September 14, 2026, allowing stays of up to 30 days for business, tourism, family visits, and transit [1] - The Shanghai Cooperation Organization (SCO) leaders have issued a statement supporting the multilateral trading system, emphasizing the importance of development and the integration of least developed countries into the trade system [1] - China aims to strengthen communication and cooperation with SCO member states to promote genuine multilateralism and push for reforms in the World Trade Organization (WTO) [1] Group 2: Social Security and Tax Policies - The Ministry of Finance and the State Taxation Administration have announced tax policies regarding the transfer of state-owned equity and cash income to bolster the social security fund, including exemptions from VAT and corporate income tax for certain transactions [2] - The policy aims to facilitate the management of state-owned assets and enhance the financial sustainability of the social security fund [2] Group 3: Software Industry Performance - In the first seven months of 2025, China's software industry generated revenue of 83,246 billion yuan, reflecting a year-on-year growth of 12.3% [3] - The total profit of the software industry reached 10,890 billion yuan, with software product revenue accounting for 21.6% of the total industry revenue [3] - Information technology services contributed 57,246 billion yuan, representing 68.8% of the overall revenue, indicating a strong performance in this sector [3] Group 4: Biopharmaceutical Industry Development - The State-owned Assets Supervision and Administration Commission (SASAC) is focusing on accelerating the development of the biopharmaceutical industry, aiming to create a national team in this field [4] - The initiative emphasizes innovation-driven development and collaboration with the Chinese Academy of Sciences to enhance the quality and competitiveness of China's biopharmaceutical sector [4]